trending Market Intelligence /marketintelligence/en/news-insights/trending/xOi6xMrAxsOItDYI-rbAgg2 content esgSubNav
In This List

Life science technology company 10x Genomics raises $448.5M in Nasdaq IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Life science technology company 10x Genomics raises $448.5M in Nasdaq IPO

10x Genomics Inc. raised $448.5 million in gross proceeds in its IPO on the Nasdaq Global Select Market.

The Pleasanton, Calif.-based life science technology company sold a total of 11.5 million shares of its class A common stock at $39 apiece. This includes an additional 1.5 million shares sold as underwriters exercised their overallotment option.

Shares of 10x Genomics began trading on the Nasdaq Global Select Market on Sept. 12 under the ticker symbol TXG.

The company, which makes instruments, consumables and software for analyzing biological systems, intends to use the net proceeds from the offering for general corporate purposes, including working capital, operating expenses and capital expenditures. A portion of the proceeds may be used to acquire businesses, products or technologies.

J.P. Morgan LLC, Goldman Sachs & Co. LLC and Bank of America Merrill Lynch were the lead joint book-running managers, while Cowen was the lead manager for the offering.